HWA
CRVO icon

HCR Wealth Advisors’s CervoMed CRVO Stock Holding History

HCR Wealth Advisors’s Portfolio CRVO Stock Details CRVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-280
Closed -$19K – 192
2021
Q1 		$19K Buy
+280
New +$23.5K ﹤0.01% 179
2020
Q4 		– Sell
-400
Closed -$25K – 271
2020
Q3 		$25K Sell
400
-133
-25% -$10.1K 0.01% 200
2020
Q2 		$38K Buy
+533
New +$32.4K 0.01% 183

Other funds holding CRVO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
RJFSA
Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return
YF
Yu Fan $97M AUM 57.2% 1-Year Est. Return

HCR Wealth Advisors's CRVO Position: Q2 2021 in Review

HCR Wealth Advisors sold out of CervoMed (CRVO) in Q2 2021, closing a stake of 280 shares — an estimated $19K sold.

HCR Wealth Advisors first reported a position in CRVO in Q2 2020 and held it in 3 quarters. The position peaked at $38K in Q2 2020. 24 funds tracked by Wall St. Rank hold CRVO as of Q2 2021.

  • HCR Wealth Advisors reported no remaining CervoMed position as of Q2 2021 after selling out during the quarter.
  • HCR Wealth Advisors sold 280 CervoMed shares in Q2 2021, an estimated $19K.
  • HCR Wealth Advisors first reported a position in CervoMed in Q2 2020 and held it in 3 quarters.
  • HCR Wealth Advisors's CervoMed position peaked at $38K in Q2 2020.
  • 24 funds tracked by Wall St. Rank held CervoMed as of Q2 2021.

Based on HCR Wealth Advisors's 13F filing for Q2 2021, filed 21 Jul 2021.